Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone payments
Voyager Therapeutics Inc.'s stock (VYGR) soared 32% early Tuesday, after the Lexington, Mass.-based biotech announced a new license agreement with Novartis Pharma AG, a unit of Novartis AG. (NVS) The companies will collaborate in advancing potential gene therapies for Huntington's disease and spinal muscular atrophy with Voyager giving Novartis license to access its Tracer capsids and other IP. Under the terms of the deal, Voyager will receive $100 million upfront, which includes $20 million for newly issued equity. Voyager will be eligible for up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products that are developed using its technology. "Voyager will be responsible for preclinical advancement and Novartis will be responsible for all clinical development and commercialization for the HD program," the company said in a statement. Voyager's stock has gained 38% in the last 12 months, while the S&P 500 has gained 24%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-02-24 0729ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks